Biohaven provides overview of clinical progress, regulatory updates, and pipeline developments at r&d day

Submitted a new drug application (nda) for troriluzole in spinocerebellar ataxia type 3 (sca3) to u.s. fda in 2q2023, marking the team's fourth nda in approximately 3 years released additional data from kv7 platform, including phase 1 safety data by dose groups for bhv-7000 that further validates differentiated profile projected phase 3 spinal muscular atrophy trial to complete enrollment in 2023 initiated phase 1 study of brain penetrant tyk2/jak1 inhibitor, bhv-8000, and anticipate beginning phase 2 trial in parkinson's disease next year highlighted robust pipeline with multiple inds planned to be filed within the next year, including pan igg degrader for multiple immune-mediated diseases in 2023 new haven, conn. , may 31, 2023 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking